How an Entrepreneur Used Artificial Intelligence to Build a Custom Cancer Vaccine for His Dog
San Francisco, Sunday, 15 March 2026.
An Australian entrepreneur bypassed traditional pharmaceutical pipelines, using consumer artificial intelligence to design a custom vaccine that successfully shrank his dying dog’s cancer tumor by half.
The $3,000 Alternative to Pharma Pipelines
Armed with Rosie’s genomic data, Conyngham utilized AlphaFold, an advanced AI system developed by Google DeepMind that predicts protein structures, to understand specific protein functions and pinpoint the mutations [1]. The algorithm then helped match these genetic anomalies to potential drug interventions, culminating in the collaborative design of a bespoke mRNA cancer vaccine alongside UNSW researchers [1][4]. This process bypassed the traditional pharmaceutical research and development pipeline, which typically requires billions of dollars and years of clinical trials to yield viable therapies [GPT]. For healthcare investors and biotech executives, Conyngham’s $3,000 expenditure represents a staggering disruption to conventional drug development economics [3][4].
Silicon Valley Takes Notice
The experimental treatment was finally administered over the Christmas break in December 2025 [1][2]. Following the initial injection and subsequent booster shots, Rosie’s major tumor shrank by half, significantly improving her quality of life and extending her timeline [1][2][4]. While medical experts caution that this isolated case serves as an experimental example rather than definitive clinical proof, the results have sent shockwaves through the technology and medical communities [4]. Conyngham is already working on a second vaccine iteration to target the remaining tumor mass [alert! ‘Current status of the second vaccine trial remains unpublished as of March 2026’] [1].